AAN 2011: Tool Predicts Disability Timeline for Progressive MS

Article

Mayo Clinic researchers can predict whether patients will suffer a faster onset of disability and counsel them to help ease anxiety.

Many patients with progressive multiple sclerosis (MS) worry how quickly the disease will progress. Now, by noting the presence of certain markers in a commonly performed diagnostic test, Mayo Clinic researchers can predict whether patients will suffer a faster onset of disability and counsel them to help ease anxiety. The research is being presented at the American Academy of Neurology meeting in Honolulu, Hawaii.

Progressive MS is a disease of the central nervous system that can damage the brain, spinal cord and optic nerves. Over time, this damage can make it difficult or impossible for patients to walk, making them reliant on mobility aids such as walkers or wheelchairs.

"In this study, we found that in patients who developed the progressive form of MS that had preceding relapses, the presence of greater production of one of these molecules, immunoglobulin G, predicted a faster onset of disability," explains Orhun Kantarci, M.D., a Mayo Clinic neurologist and the study's lead author. As physicians better predict the onset of disability, they can better counsel patients by providing answers in a time of uncertainty.

The study looked at cerebrospinal fluid (CSF) test results from a sample of 281 progressive MS patients seen at Mayo Clinic from 2002 to 2007. In general, CSF test results help physicians when the diagnosis is uncertain. For this study, researchers analyzed CSF test results and noticed a relationship between a faster disability rate and abnormally high levels of two proteins — oligoclonal band and immunoglobulin-G molecule. If patients had the progressive form of MS with proceeding relapses, and their CSF results showed an elevated protein, researchers concluded they will have a faster rate of disability.

The study is a significant step forward in predicting disability outcomes, says researcher Junger Tang, M.D., a neurology fellow at Mayo Clinic. The next step is further research to confirm the results, he says.

Source: Mayo Clinic

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.